MNTR.PK - Mentor Capital

[mlgreen8753]

Mentor Capital is a primary stakeholder in Quantum Immunologics (QI), a privately held company with FDA authorized clinical trials underway for a new breast cancer treatment called immunotherapy. The treatment sensitizes dendritic cells to expose a protein found only on cancer infected cells. The intention of this treatment is to help the immune system identify and destroy these specific cells. Because the capital received from MNTR.PK stock will be used to fund QI, an investment in Mentor Capital is essentually an investment in further breast cancer research in QI as implied in an article posted on Breast Cancer Investing. It is likely that breast cancer supporters will take an interest in this investment opportunity.